Phanuel Pursuits

Phanuel Pursuits is a private biotechnology company focused on discovering and developing next-generation therapies for neurological and neuropsychiatric disorders. The company was founded by Dr. David Bredt, a distinguished neuroscientist known for his pioneering work on the molecular organization of the synapse, including the discovery of PSD-95. Phanuel Pursuits leverages proprietary insights into synaptic plasticity and the postsynaptic density to identify novel drug targets for conditions with high unmet needs, such as depression and schizophrenia. Operating primarily in a stealth capacity, the company is backed by MPM BioImpact and focuses on small molecule modalities. Its research aims to restore functional signaling in the brain by modulating protein-protein interactions within neuronal scaffolds.